Related Experiment Videos
Cerebrospinal fluid markers in neurological disorders
A R Massaro1, G Scivoletto, P Tonali
1Istituto di Neurologia, Università del Sacro Cuore, Roma.
Italian Journal of Neurological Sciences
|December 1, 1990
Summary
Cerebrospinal fluid (CSF) markers, including myelin basic protein and neuron-specific enolase, aid in tracking neurological disease progression and treatment efficacy. These protein biomarkers offer valuable insights for both clinical evaluation and research into disease mechanisms.
Area of Science:
- Neurology
- Biochemistry
- Clinical Diagnostics
Background:
- Cerebrospinal fluid (CSF) analysis is crucial for monitoring neurological disorders.
- Identifying reliable biomarkers is essential for assessing disease activity and treatment response.
- Understanding pathobiological evolution requires robust research parameters.
Purpose of the Study:
- To review key cerebrospinal fluid (CSF) proteins as biomarkers for neurological conditions.
- To provide data on the biological properties and analytical methods for these markers.
- To evaluate the clinical usefulness of specific CSF proteins in disease management and research.
Main Methods:
- Literature review of established CSF protein markers.
- Compilation of data on biological characteristics and analytical techniques.
- Assessment of clinical utility based on existing research.
Main Results:
- Myelin basic protein (MBP) is a marker of demyelination.
- S-100 protein and glial fibrillary acidic protein (GFAP) indicate glial cell activation.
- Neuron-specific enolase (NSE) is a marker of neuronal damage.
Conclusions:
- CSF protein markers are valuable for evaluating treatment efficacy and disease progression.
- These biomarkers are instrumental in research for understanding neurological disease pathobiology.
- The reviewed proteins offer a basis for improved diagnostic and prognostic strategies in neurology.